Aktienanalyse zu Insmed Inc (INSM)INSMInsmed Inc

Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Insmed Inc appears to be a good buy right now, with a current price of $118.54 and a gross margin of 83.71%, indicating strong profitability potential. The recent approval of Brinsupri in Japan is a significant positive catalyst that could drive future revenue growth. Additionally, the stock has shown a 296% year-over-year revenue increase to $425.5 million in Q2 2026, which reflects robust demand for its products. However, the main risk is the negative earnings per share of -0.06, which indicates ongoing losses that investors should monitor closely.

8 analysts cover INSM: 7 rate it Buy, 1 Hold and 0 Sell. The average price target is 219.50.